Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sobi To Appeal Against EMA Rejection For Emapalumab

Executive Summary

The company says its drug has demonstrated a positive benefit-risk profile in primary HLH in a post-approval real-life setting in the US since Food and Drug Administration approval in 2018.

You may also be interested in...



EMA Recommends Stemline’s Elzonris After Initial Rejection

While the European Medicine Agency now recommends that Elzonris should be approved in the EU, Stemline Therapeutics will have to submit the results of a study based on a registry of patients with blastic plasmacytoid dendritic cell neoplasm.

EMA Dashes Sobi’s EU Gamifant Marketing Hopes

The European Medicine Agency has stood firm on its decision to recommend against pan-EU marketing approval for Gamifant.

Winners And Losers: A Deep-Dive Into The EMA’s PRIME Scheme

Nine of the 70 medicines for unmet medical needs that have to date won a place on the European Medicines Agency’s PRIME scheme are now approved for sale in the EU, and two more approvals are expected soon. Meanwhile, most applications for a "priority medicine" designation are still missing the mark.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS142609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel